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The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride 
channel localized primarily at the apical or luminal surfaces of epithelial cells that line the 
airway, gut, and exocrine glands; it is well established that CFTR plays a pivotal role in 
cholera toxin (CTX)-induced secretory diarrhea. Lysophosphatidic acid (LPA), a naturally 
occurring phospholipid present in blood and foods, has been reported to play a vital role in a 
variety of conditions involving gastrointestinal wound repair, apoptosis, inflammatory bowel 
disease, and diarrhea. Here we show, for the first time, that type 2 LPA receptors (LPA
 
2
 
) are 
expressed at the apical surface of intestinal epithelial cells, where they form a macromolecular 
complex with Na
 
 
 
/H
 
 
 
 exchanger regulatory factor–2 and CFTR through a PSD95/Dlg/ZO-1–
based interaction. LPA inhibited CFTR-dependent iodide efflux through LPA
 
2
 
-mediated G
 
i
 
 
pathway, and LPA inhibited CFTR-mediated short-circuit currents in a compartmentalized 
fashion. CFTR-dependent intestinal fluid secretion induced by CTX in mice was reduced 
substantially by LPA administration; disruption of this complex using a cell-permeant 
LPA
 
2
 
-specific peptide reversed LPA
 
2
 
-mediated inhibition. Thus, LPA-rich foods may represent 
an alternative method of treating certain forms of diarrhea.
 
Infectious diarrhea disease is second only to
cardiovascular disease as cause of death (1) and
is one of the major causes of morbidity and
mortality among children. It accounts for 21%
of deaths of children who are younger than 5
yr of age in the developing world, and causes
2.5 million deaths per year (2). Although inci-
dence rates increase with a country’s decreasing
socioeconomic status, infectious diarrhea also
is a common illness in Western industrialized
societies, particularly among vulnerable groups
of young children, elderly adults, and people
who have underlying diseases (3). Two major
organisms that cause infectious diarrhea in
humans are 
 
Escherichia coli
 
 and 
 
Vibrio cholerae
 
;
their secreted toxins (heat stable or heat labile
toxin, and cholera toxin [CTX], respectively)
influence gastrointestinal epithelial cell function
and induce diarrhea by numerous mechanisms
(4). CTX is likely the most recognizable entero-
toxin that causes secretory diarrhea by stimu-
lating transepithelial Cl
 
 
 
 secretion, thereby in-
creasing the osmotic impetus for fluid secretion
(5). Diarrhea also can result from an increased
immunoinflammatory response that is triggered
by cytokine or mediator (e.g., adenosine; ADO)
secretion from intestinal mucosal inflammatory
cells in response to luminal factors (e.g., dietary
or bacterial antigens). This also is a common
symptom that is associated with the major gas-
trointestinal disorders, such as inflammatory
bowel disease (IBD) afflicting 
 
 
 
1 million
Americans (6), and irritable bowel syndrome,
which affects 15 million Americans (7). Mucosal
inflammation plays an essential role in the patho-
genesis of irritable bowel syndrome and IBD (8,
9). ADO, an inflammatory mediator, stimulated
chloride secretion in several types of secretory
epithelia, including mammalian ileum and colon
(10, 11).
Cystic fibrosis transmembrane conductance
regulator (CFTR) is a cAMP-regulated chlo-
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ride channel that is localized primarily at the apical or lumi-
nal surfaces of epithelial cells that line the airway, gut, and
exocrine glands (12); it is well-established that CFTR plays a
pivotal role in CTX-mediated diarrhea (13). Lysophospha-
tidic acid (LPA), a naturally occurring phospholipid present
in blood and foods (14, 15), acts on the LPA receptors
(LPA
 
1
 
, LPA
 
2
 
, and LPA
 
3
 
), which are G-protein coupled re-
ceptors that belong to the endothelial cell differentiation
gene family (16–18). LPA was reported to play an essential
role in a variety of conditions involving gastrointestinal
wound repair, apoptosis, IBD, and diarrhea (19–23). In the
present study, we investigated how LPA-elicited LPA
 
2
 
-
mediated signaling might regulate CFTR function in the
gut, and evaluated the usefulness of LPA in preventing
CTX-induced secretory diarrhea in mice.
 
RESULTS
LPA
 
2
 
 and Na
 
 
 
/H
 
 
 
 exchanger regulatory factor–2 
are expressed in intestinal epithelial cells and localized 
primarily at the apical cell surfaces
 
Using RT-PCR, we demonstrated that the transcripts for
LPA
 
1
 
 and LPA
 
2
 
, but not LPA
 
3
 
, were present in mouse intesti-
nal tissue (Fig. S1, A and B, available at http://www.jem.org/
cgi/content/full/jem.20050421/DC1). HT29-CL19A (co-
lonic epithelial cells) and Calu-3 (airway serous gland epithe-
lial cells) also expressed LPA
 
2
 
 transcript (Fig. S1 C), and the
expression of LPA
 
2
 
 in plasma membranes was verified using an
LPA
 
2
 
-specific antibody (Fig. 1 A). LPA
 
2
 
 was localized pre-
dominantly to the apical surfaces of HT29-CL19A cells by
confocal microscopy (Fig. 1 B, top) and surface biotinylation
(24) (Fig. 1 C, top), where it colocalized with CFTR (Fig. 1
B, middle; Fig. 1 C, bottom). An apical membrane marker,
ezrin, was used to confirm the subcellular (apical) localization
of LPA
 
2
 
 and CFTR (Fig. 1 B, bottom).
LPA
 
2
 
 was reported to interact specifically with Na
 
 
 
/H
 
 
 
exchanger regulatory factor (NHERF)-2 (25, 26), a PSD95/
Dlg/ZO-1 (PDZ) domain-containing protein that has been
well-documented to cluster signaling molecules into su-
pramolecular complexes (27). Here we showed that
NHERF2 was expressed at various levels in epithelial cells
(e.g., HT29-CL19A, Calu-3, mouse intestine epithelial cells)
(Fig. 1 D, top right). This isoform-specific antibody did not
cross-react with NHERF1, which shares 
 
 
 
50% sequence
identity with NHERF2 (Fig. 1 D, top left). NHERF2 also
was localized to the apical surfaces in HT29-CL19A cells
(Fig. 1 D, bottom) where CFTR and LPA
 
2
 
 reside (Fig. 1 B).
 
LPA
 
2
 
 binds NHERF2 with the highest affinity
 
The COOH-terminal tails of LPA
 
1
 
 and LPA
 
2
 
, but not LPA
 
3
 
,
contain a consensus for the PDZ motif, the short COOH-
Figure 1. LPA2 and NHERF2 are expressed in epithelial cells and 
localized primarily at the apical cell surfaces. (A) LPA2 expression in 
crude plasma membranes prepared from HT29-CL19A and Calu-3 cells. 
(B) Apical localization of LPA2, CFTR, and ezrin in polarized HT29-CL19A 
cells by confocal microscopy. AP, apical; BL, basolateral. (C) Expression of 
LPA2 and CFTR in apical membranes of HT29-CL19A cells by surface bio-
tinylation method. Smaller amounts of LPA2 also were observed in the 
basolateral membrane. (D) NHERF2 expression and apical localization in 
epithelial cells. The nucleus was stained with propidium iodide solution 
(bottom). 
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terminal sequences that specifically interact with the PDZ-
binding domains (usually 
 
 
 
70–90 amino acid sequences) of
PDZ proteins, including NHERF2 (28) (Fig. S2 A, boxed
area, available at http://www.jem.org/cgi/content/full/
jem.20050421/DC1). Thus, LPA
 
1
 
 and LPA
 
2
 
 are likely can-
didates with which PDZ-domain–containing proteins can
interact, modulate, and mediate their signals. Pull-down
assays demonstrated that LPA
 
2
 
 interacted directly with
NHERF2 with the highest affinity (Fig. S2, B and C), as re-
ported previously (25, 26).
 
LPA inhibits CFTR-dependent iodide efflux through LPA
 
2
 
 
receptor–mediated G
 
i
 
 pathway
 
Although all three LPA receptors (LPA
 
1
 
, LPA
 
2
 
, and LPA
 
3
 
)
respond to LPA, LPA
 
2
 
 has the highest affinity to the lipid
(29), and leads to the activation of at least three distinct
G-protein pathways: G
 
i
 
, G
 
q
 
, and G
 
12/13
 
 (17, 18). Activation
of these receptors by LPA results in inhibition of the adenyl-
ate cyclase (AC) pathway, which, in turn, decreases cAMP lev-
els (16–18). The G
 
i
 
 activation pathway of the receptor is
summarized in Fig. S2 D.
Given that LPA
 
2
 
 binds NHERF2 (25, 26) (Fig. S2, B
and C) and our previous demonstration that NHERF2 can
form a macromolecular complex with CFTR (30), we hy-
pothesized that LPA might regulate CFTR Cl
 
 
 
 channel
function which is regulated by cAMP. To test this, the effect
of LPA on CFTR activity was monitored using iodide efflux
measurements (31). Calu-3 cells, like HT29-CL19A cells,
express all three proteins (CFTR, NHERF2, and LPA
 
2
 
) at
the apical surfaces, and show a robust CFTR function be-
cause they express a higher level of CFTR compared with
HT29-CL19A cells. Therefore, they represent a better
model cell line for demonstrating the effects of LPA on
CFTR function. LPA pretreatment (20 
 
 
 
M LPA 18:1 for 4
min before ADO addition) reduced the response of Calu-3
cells to cAMP-elevating ligand ADO in a dose-dependent
manner (Fig. 2, A and B). CFTR activity was not inhibited
by a structurally related lysophospholipid, sphingosine-1-
phosphate (S1P; data not shown), whose receptors also are
expressed in the gut epithelium but lack PDZ domain, nor
by a related lipid—phosphatidic acid (PA) (Fig. 2 B)—which
is not a ligand for LPA receptors (16). Similar results also
were observed with HT29-CL19A cells (unpublished data).
These results clearly demonstrate that LPA can inhibit
CFTR function in epithelial cells.
To test the hypothesis that the inhibition of CFTR func-
tion by LPA is receptor mediated, we pretreated cells with
pertussis toxin (PTX), which catalyzes the ADP-ribosylation
of the G
 
i
 
 
 
 
 
-subunit, and specifically disrupts the G
 
i
 
 pathway
(32). PTX pretreatment reversed LPA-elicited inhibition of
CFTR function in response to ADO in Calu-3 cells (Fig. 2
C) and HT29-CL19A cells in a dose-dependent manner
(not depicted). Therefore, it is likely that inhibition of
CFTR function by LPA is receptor mediated through the G
 
i
Figure 2. LPA inhibits CFTR-dependent iodide efflux through LPA2 
receptor–mediated Gi pathway. (A) Representative ADO-activated CFTR-
mediated iodide efflux in Calu-3 cells treated with LPA 18:1 (20  M, BSA-
complexed). (B) ADO-activated iodide efflux in LPA 18:1- or PA-pretreated 
Calu-3 cells. Note: the peak efflux is shown (5-min time point). (C) Calu-3 
cells were pretreated with PTX (100 and 200 ng) for 24 h at 37 C and 
subjected to iodide efflux activated by ADO in the presence of LPA 18:1 
(20  M). (D) Peak efflux of iodide in response to ADO in Calu-3 cells that 
were treated with various LPA analogs (20  M). Results are presented as 
mean   SEM (n   4–6 each group). *P   0.05; **P   0.01. 
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pathway. Several fatty acid analogs of LPA were screened,
and the rank order of inhibition was LPA 20:4 
 
 
 
 LPA 18:2 
 
 
 
LPA 18:1 (Fig. 2 D), which matches their relative abundance
in human serum (33).
 
LPA inhibits CFTR-dependent short-circuit currents 
in polarized epithelial cells and mouse intestinal 
epithelia preparation
 
The effect of LPA on CFTR-dependent short-circuit cur-
rents (I
 
sc
 
) also was monitored on polarized epithelial mono-
layers (30). LPA substantially inhibited CFTR-dependent
Cl
 
 
 
 currents in response to ADO activation in HT29-
CL19A cells (Fig. 3 A) and Calu-3 cells (Fig. 3 B). I
 
sc
 
 stimu-
lated by ADO (Fig. 3 C) or 8-(4-chlorophenylthio)-cyclic
AMP (cpt-cAMP) (a cell-permeant isoform of cAMP, a sub-
maximal CFTR activating dose was used; Fig. S3 A, available
at http://www.jem.org/cgi/content/full/jem.20050421/
DC1) also was inhibited, in a dose-dependent fashion, in
LPA-pretreated epithelia that were isolated from mouse in-
testine (34) (Fig. S3 B). The inhibitory effect of LPA on
CFTR Cl
 
 
 
 currents in the intestinal epithelia was more
prominent when CFTR was activated at lower concentra-
tions of ADO (Fig. 3 D), whereas LPA failed to inhibit the
channel function significantly when CFTR was activated
maximally by a cocktail agonist mixture in intestinal epithe-
lia (Fig. 3, C and D) and cultured epithelial cell monolayers
(Fig. S3 C). The I
 
sc
 
 in response to ADO was inhibited by
CFTR blockers, diphenylamine-2-carboxylate (DPC) (Fig.
3 B) and glybenclamide (not depicted). PA and S1P did not
inhibit the CFTR Cl
 
 
 
 channel (unpublished data). ADO is
produced at almost 1 
 
 
 
M in unstressed tissue, whereas it can
be 
 
 
 
100 
 
 
 
M in inflamed or ischemic tissues (35). Under
conditions of inflammation (e.g., IBD), ADO is secreted
into the gut, which activates CFTR and leads to increased
chloride and fluid secretion into the gut (10, 11, 36).
 
LPA inhibits CFTR single-channel Cl
 
 
 
 currents 
in a compartmentalized fashion
 
The intracellular cAMP accumulation in cell extracts in re-
sponse to various agonists in Calu-3 cell monolayers also was
monitored. The cAMP accumulation at a lower concentra-
tion of ADO (2 
 
 
 
M) was almost indistinguishable from that
in unstimulated cells (Fig. 4 A). However, CFTR is activated
at this ligand concentration (Fig. 3 B, top), and LPA can in-
hibit channel activity substantially (Fig. 3 B, bottom). Our re-
sult is consistent with the concept that upon ADO stimula-
tion, cAMP is likely to be generated in a compartmentalized
manner, localized to the apical membrane (37). At a higher
ADO concentration (20 
 
 
 
M), when the cAMP within the
cell increased globally (Fig. 4 A), LPA inhibition of CFTR
function became less obvious (Fig. 3 B, compare the maximal
I
 
sc
 
 response between control and LPA-treated cells). In addi-
tion, although LPA did not inhibit CFTR function in Calu-3
cells that were activated maximally by a cocktail mixture (Fig.
Figure 3. LPA inhibits CFTR-dependent Isc in polarized epithelial cells 
and isolated mouse intestinal epithelia. (A) Representative traces of CFTR-
mediated Isc in response to ADO in HT29-CL19A cells without (top) or with 
(bottom) LPA 20:4 pretreatment. (B) Isc in response to ADO in Calu-3 cells. 
DPC (500  M) was used as a CFTR blocker toward the end of the experiment. 
(C) Isc in response to ADO and cocktail (20  M forskolin; 100  M IBMX) in 
mouse intestinal epithelia. (D) Peak Cl  currents (% control) activated by ADO 
or cocktail in mouse intestine epithelia summarized from (C) (n   4).JEM VOL. 202, October 3, 2005 979
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S3 C), LPA significantly reduced the intracellular cAMP ac-
cumulation compared with the control (Fig. S3 D). This may
have been because although the total intracellular cAMP level
was reduced significantly by LPA, it was still high enough to
activate CFTR almost maximally. Altogether, our data
suggest that localized LPA signaling and cAMP accumula-
tion within a compartmentalized domain under the apical
epithelial cell membranes.
Cell-attached single-channel recordings also were per-
formed; they confirmed that LPA inhibited cAMP genera-
tion in a compartmentalized fashion. ADO, forskolin, or
cpt-cAMP was applied in the pipette to evoke a localized
generation of cAMP or in the bath to elicit a global elevation
of the second messenger (37). The CFTR channel was acti-
vated when 2  M ADO was added in the pipette, but not
when it was added to the bath (Fig. 4, B and C). In cells that
were pretreated with LPA, the stimulatory effect of ADO (2
 M, applied in the pipette) on the channel activity was in-
hibited (Fig. 4, B and C). In contrast, when 10  M forskolin
was used in the pipette or the bath (leading to a global in-
crease in cAMP), LPA no longer attenuated channel func-
tion (Fig. 4, B and C). Similar results were observed when
cpt-cAMP was used to activate the channel. A lower con-
centration of cpt-cAMP (20  M) stimulated localized
CFTR activity that could be inhibited by LPA, whereas a
higher concentration of cpt-cAMP (200  M) led to global
stimulation that could not be attenuated by LPA (Fig. S4, A
and B, available at http://www.jem.org/cgi/content/full/
jem.20050421/DC1). These single-channel recordings clearly
confirmed the findings that LPA inhibits CFTR-mediated
Cl  currents in a compartmentalized fashion.
LPA inhibits CFTR-dependent CTX-induced mouse intestinal 
fluid secretion in vivo
To provide proof of concept that LPA could be used in a
therapeutic setting, we tested the effect of LPA on CTX-
induced diarrhea in a mouse model (38). Binding of the
cholera enterotoxin from V. cholerae to the intestinal entero-
cyte leads to ADP-ribosylation of the Gs  -subunit, which,
in turn, activates AC of enterocytes and leads to an elevation
of cAMP (39, 40). Thus, the apical membrane CFTR Cl 
channel is activated, which results in a voluminous Cl  and
fluid secretion that can be fatal, if untreated (5, 39). In li-
gated ileal loops, CTX treatment elicited fluid accumulation
in a dose-dependent manner (Fig. 5 A). A linear increase in
cAMP accumulation within the loop tissue was elicited by
the increasing amounts of CTX (injected into the ileal loops)
in the range of 0–10  g (Fig. S5 A, available at http://
www.jem.org/cgi/content/full/jem.20050421/DC1). These
results are consistent with the reports that CTX can induce a
dose-dependent increase in intracellular cAMP production
in cultured cells (41–43) as well as a dose-dependent fluid
Figure 4. LPA inhibits CFTR-dependent Cl  currents in a compart-
mentalized fashion. (A) Intracellular cAMP levels in Calu-3 cells under vari-
ous conditions. (n   4). (B) Single-channel recordings of CFTR in cell-attached 
configuration in HT29-CL19A cells under different recording conditions as 
indicated. C, channel closed state; FSK, forskolin; O, channel open state. 
(C) Summary of CFTR channel open probability (NPo). **P   0.01; ***P   0.001.LPA REGULATES CFTR FUNCTION IN THE GUT | Li et al. 980
accumulation in nonligated intestine in vivo (44). LPA treat-
ment significantly reduced the fluid accumulation in the
toxin-treated intestinal loops in a dose-dependent fashion
(Fig. 5 B). PA (10–100  M) was used as a negative control
in these experiments, and showed no effect in reversing
CTX action (i.e., fluid accumulation) (unpublished data).
Figure 5. LPA inhibits CFTR-dependent intestinal fluid secretion 
induced by CTX. (A) Representative mouse ileal loops 6 h after luminal 
injection with CTX (pictures). The bar graphs (bottom) show the averaged loop 
weight (n   3). (B) Representative ileal loops 6 h after luminal injection of CTX 
without or with LPA 20:4 (pictures). The bar graphs (bottom) show the 
averaged loop weight (n   3–5). (C) Representative segments of mouse 
whole small intestine from open-loop model 6 h after oral gavage of CTX 
(pictures). Bar graphs show averaged fluid accumulation in the whole small 
intestine. Data shown as entire intestine weight before/intestine weight after 
luminal fluid removal (n   3–4). (D) Representative segments of mouse 
small intestine from open-loop model 6 h after simultaneous oral gavage of 
CTX and LPA 20:4. Bar graphs show averaged fluid accumulation in the whole 
small intestine (n   3–4). (E) CTX-induced intestinal fluid secretion after 
subsequent oral administration of LPA 20:4 in mouse open-loop model. 
Oral administration of LPA 20:4 was performed at different time points 
after CTX feeding (n   5–8). (F) Representative ileal loops 6 h after luminal 
injection of CTX without or with LPA 20:4 in LPA2 knockout mice (pictures). 
The bar graphs (bottom) show the averaged loop weight (n   5–6). *P   0.05; 
**P   0.01; ***P   0.001.JEM VOL. 202, October 3, 2005 981
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Additionally, in an open-loop mouse model, oral adminis-
tration of CTX induced a marked fluid accumulation within
the whole small intestine in a dose-dependent manner (Fig. 5
C). This was attenuated substantially by simultaneous admin-
istration of LPA in a dose-dependent fashion (Fig. 5 D). Bio-
logically effective portions of orally applied LPA remain intact
in the whole intestine during the procedure (Fig. S5 B). To
explore the therapeutic potential of LPA treatment of diarrhea
and to exclude the possibility that LPA might interact directly
with CTX or prevent binding of CTX to the ganglioside re-
ceptor (4), we also tested LPA-mediated inhibition of intesti-
nal fluid accumulation in mice that were prestimulated by
CTX. Mice that received a dose of LPA at 0–2 h after expo-
sure to CTX also showed a significant decrease in intestinal
fluid secretion (Fig. 5 E). Ileal loop experiments also were
performed in LPA2 knockout mice. The inhibitory effect of
LPA on CFTR-dependent fluid secretion was not observed
in LPA2 knockout mice (Fig. 5 F). These results clearly dem-
onstrate that inhibition of CFTR-mediated secretory diarrhea
by LPA requires the LPA2 receptor.
LPA2 forms a macromolecular complex with CFTR mediated 
by way of NHERF2
We hypothesized that the interaction between CFTR and
LPA2 likely was mediated by NHERF2. To test this, we as-
sembled a macromolecular complex of LPA2, NHERF2,
and CFTR in vitro, which is represented schematically in
Fig. 6 A (24). A macromolecular complex was formed be-
tween maltose binding protein (MBP)-C–CFTR, glu-
tathione S-transferase (GST)-NHERF2, and LPA2 (Fig. 6
B). MBP-C–CFTR did not bind directly to LPA2 nor did
the complex form in the presence of GST or MBP alone
(Fig. 6 B). The complex formation was PDZ-motif depen-
dent. Mutating the last amino acid (aa) of LPA2 (L351A) re-
duced the complex formation, whereas deleting the last
three aa’s of LPA2 ( STL) completely eliminated the macro-
molecular complex (Fig. 6 C).
The in vitro macromolecular complex assembly does not
indicate whether the complex exists in native membranes;
therefore, cross-linking experiments were performed to cap-
ture the complex in overexpressing cells (30). Fig. 6 D shows
a cross-linked complex that contains CFTR and LPA2 in
BHK cells that express endogenous NHERF2. We next im-
munoprecipitated CFTR from cultured epithelial cells and
demonstrated that LPA2 and NHERF2 were present in the
complex in HT29-CL19A and Calu-3 cells (Fig. 6 E). These
studies suggest that a macromolecular complex of LPA2–
NHERF2–CFTR likely is present in the apical surface of
epithelial cells.
Disruption of the macromolecular complex 
of LPA2–NHERF2–CFTR using an LPA2-specific peptide 
prevents LPA2-mediated CFTR inhibition by LPA
We next determined if a physical association of LPA2 and
CFTR by way of NHERF2 was essential for the LPA-elic-
ited inhibition of the Cl  channel. To disrupt the complex,
we delivered an LPA2 isoform-specific peptide containing
the PDZ motif (last 11 aa’s of LPA2; aa’s 341–351), using the
Chariot system (45), into polarized epithelial cells before Isc
measurements. Isc in response to ADO in the presence of
LPA was monitored. LPA2-specific peptide significantly pre-
vented the LPA-elicited inhibition of CFTR-dependent Cl 
Figure 6. LPA2 forms a macromolecular complex with CFTR medi-
ated through NHERF2. (A) Pictorial representation of the macromolecular 
complex assay (see Materials and methods for details). (B) Macromolecular 
complex of MBP-C–CFTR, GST–NHERF2, and Flag-tagged LPA2. (C) Macro-
molecular complex of MBP-C–CFTR, GST–NHERF2, and Flag-tagged LPA2, 
LPA2– STL, or LPA2–L351A. (D) BHK or BHK–CFTR cells transiently trans-
fected with Flag-LPA2 were cross-linked using 1 mM DSP and coimmuno-
precipitated using anti-CFTR antibody (NBD-R) and probed for LPA2. (E) Cell 
lysates from HT29-CL19A (left) and Calu-3 (right) were coimmunoprecipi-
tated using anti-CFTR antibody (R1104) and probed for NHERF2 and LPA2. 
LPA2 blot was visualized using SuperSignal West Femto Maximum Sensitiv-
ity Substrate because of the weak signal (Pierce Chemical Co.).LPA REGULATES CFTR FUNCTION IN THE GUT | Li et al. 982
currents in polarized HT29-CL19A (Fig. 7 A) and Calu-3
monolayers (Fig. S6 A, available at http://www.jem.org/
cgi/content/full/jem.20050421/DC1). At the end of the
experiment, the epithelial cells were fixed and immuno-
stained to confirm the delivered peptide (Fig. 7 B and Fig.
S6 B). Other peptides (CFTR peptide aa’s 107–117) were
used as a negative control (unpublished data). We also dem-
onstrated that the LPA2 peptide could compete with MBP–
LPA2 C-tail for binding to NHERF2 in a dose-dependent
manner (Fig. 7 C).
DISCUSSION
In the present study, by performing a series of in vitro, ex
vivo, and in vivo experiments, we investigated the mechanism
of how the macromolecular complex of CFTR, NHERF2,
and LPA2 regulates the channel function. This is the first study
to show that a macromolecular complex (CFTR–NHERF2–
LPA2) formed in vitro is also physiologically and functionally
relevant in vivo. We have made a compelling case to demon-
strate that (a) there is a physical interaction among CFTR,
NHERF2, and LPA2; (b) this interaction is functionally rele-
vant in inhibiting the CFTR function; and (c) such protein–
protein interactions are functionally relevant in the normal
physiology of the gut. The relevance of these studies will be in
trying to prevent secretory diarrhea, which is prevalent in de-
veloping countries, with 1.5 billion episodes of diarrhea and 4
million associated deaths in children annually (46).
We tested the effect of LPA on CFTR channel function
under various conditions. For cultured cells or polarized cell
monolayers, we used LPA of 0–40  M, which is within the
physiologic concentrations of LPA in blood serum (range,
5–50   M) that was reported previously (47, 48). In the
open-loop experiments, the maximal dose of LPA that we
delivered into the mouse stomach was 1 mg/kg body
weight, which is similar to the suggested dose for various di-
etary supplements (e.g., vitamins, minerals).
ADO is an endogenous purine nucleoside that is gener-
ated at sites of tissue stress and injury, including inflamma-
tion, ischemia, and tissue remodeling. Following its produc-
tion, ADO diffuses to the surrounding cells, where it binds
to the ADO receptors, and acts as a paracrine factor with di-
verse effects on a variety of organ systems. It was reported
that in the intestinal lumen, ADO is produced in crypt ab-
scesses during active inflammation by the interaction of neu-
trophils with the intestinal epithelia, whose ectonucleoti-
dases convert neutrophil-derived ATP into ADO, which
Figure 7. Disruption of the macromolecular complex of LPA2-
NHERF2–CFTR using a LPA2-specific peptide prevents LPA2-mediated 
CFTR inhibition by LPA. (A) Isc in response to ADO in HT29-CL19A cells 
with or without LPA2-specific peptide delivered before Isc measurement. 
Cells in both groups were pretreated with LPA 20:4 (25  M) for 30 min 
before activating with ADO. (B) Immunofluorescence micrographs of 
HT29-CL19A cells from (A) showing the LPA2-specific peptide delivered 
(top; green). The nucleus was stained with propidium iodide (red). HT29-CL19A 
cells express endogenous LPA2 (bottom). (C) NHERF2 binding to LPA2 in the 
presence of LPA2-specific peptide. A curve showing the averaged band density 
also is presented. *P   0.05; **P   0.01 compared with control (n   3).JEM VOL. 202, October 3, 2005 983
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acts through the A2b ADO receptor subtype to induce vec-
torial chloride transport (49–51). Based on these observations,
it was hypothesized that luminal ADO may be involved in
secretory diarrhea that is elicited in pathophysiologic states,
such as parasitic or allergic diseases, and hypereosinophilic
syndromes (52, 53). ADO is produced at almost 1  M in
unstressed tissue, whereas in inflamed or ischemic tissues it
can be  100  M (35). In light of extensive literature sup-
port for the physiologic and pathophysiologic role of ADO,
our application of 0.2–100  M of this ligand is well within
the (patho)physiologic range. In addition to ADO, we also
used cpt-cAMP at submaximal CFTR activating conditions
and forskolin (increases cAMP globally at 10  M concentra-
tion) as agonists.
It was demonstrated that cAMP accumulation inside cells
is inhibited by LPA treatment (54, 55). In this study, we also
monitored cAMP levels under various conditions. We ob-
served that upon stimulation with low concentration of ADO
(2  M), cAMP accumulation inside polarized epithelial cells
(Calu-3) was almost indistinguishable from that of unstimu-
lated cells (Fig. 4 A). However, CFTR is functional under
these conditions and LPA can inhibit channel activity signifi-
cantly (Fig. 3 B). Our data are consistent with the published
results of Stutts’s group (37), who demonstrated a compart-
mentalized signaling from the receptor (A2b) to the channel
(CFTR) using electrophysiologic methods. This group re-
ported that CFTR chloride channel function was observed
upon stimulation of the cells by a low concentration of ADO
(1  M); the accumulation of cAMP inside the cell was not sig-
nificantly higher than that from unstimulated control cells (37).
In the present study, we found that LPA efficiently inhibits
CFTR function (in response to 2  M ADO; Fig. 3 B) with-
out causing a decrease in the global cAMP accumulation in
the cell (Fig. 4 A). Our results support the notion that cAMP
likely is generated in a compartmentalized pocket upon stimu-
lation by receptor-mediated agonists (ADO). However, when
the ADO level was increased to 20  M, we observed that the
CFTR function increased slightly compared with 2  M
ADO, but there was a significant increase in cAMP accumula-
tion inside the cell (global cAMP accumulation). Although
there is a significant decrease in cAMP accumulation with
LPA treatment, the Isc is not significantly different (in the pres-
ence or absence of LPA); this suggests that a global increase in
cAMP may offset CFTR inhibition that is elicited by LPA.
LPA inhibition of CFTR function is most prominent when
tested at a low concentration of ADO in the polarized mono-
layers (0.2–2  M; Fig. 3, A and B) and in intestinal epithelia
(2–40  M; Fig. 3, C and D), or at a submaximal activating dose
of cpt-cAMP (20–100  M) in isolated intestinal epithelia (Fig.
S3 A). This is because polarization of epithelia leads to the accu-
rate targeting of the channel (CFTR) and the receptor (LPA2)
to the apical surfaces, compared with nonpolarized cells. In ad-
dition, in Ussing chamber experiments, the CFTR-mediated Cl 
currents (short-circuit currents) were monitored in real time,
and we could titrate various concentrations of the agonists and
monitor the CFTR response that shows maximum inhibition
by LPA. In contrast, cells that were used for iodide efflux mea-
surement (Fig. 2, A–D) were grown in 60-mm dishes and were
not polarized. Due to the experimental limitations, we had to
choose a concentration of ADO (2  M). cpt-cAMP used in
this study (Fig. S3 A) activated CFTR submaximally ( 50% of
maximum activating cocktail). Therefore, external addition of a
low concentration of cpt-cAMP would be very similar to
cAMP accumulation observed with low concentrations of ago-
nists, such as ADO, although ADO would likely generate a
more compartmentalized cAMP accumulation.
Diarrhea is the most common gastrointestinal disorder. It is
well-established that CFTR plays a central role in this process
(5, 13, 36). Any reagent or factor that augments CFTR activity
(e.g., cAMP in CTX-induced diarrhea) at the luminal surface of
the colonic epithelial cells is likely to lead to diarrhea. Con-
versely, factors that inhibit the CFTR Cl  channel are likely to
be beneficial in cases of CFTR-induced diarrhea. Given that
LPA2 is expressed in the gut, localized to the apical surface, and
activates the Gi pathway and leads to decreased cAMP accumu-
lation, we propose a novel model (Fig. 8). According to our hy-
pothesis, LPA2 and CFTR are associated physically with
NHERF2, which clusters LPA2 and CFTR into a macromo-
lecular complex at the apical plasma membranes of epithelial
cells. This macromolecular complex is the foundation of func-
tional coupling between LPA signaling and CFTR-mediated
Cl  transport. The model predicts that if the physical association
is disrupted, functional coupling will be compromised. Upon
LPA stimulation of the receptor, AC is inhibited through the Gi
pathway, which leads to a decrease in cAMP level. This de-
creased local or compartmentalized accumulation of cAMP re-
sults in the reduced activation of Cl  channel in the vicinity by
CFTR agonists (e.g., ADO). Our findings shed light on the de-
tailed mechanism that underlies the transduction pathway of the
LPA2 agonists, and helps to clarify how LPA inhibits CFTR-
dependent Cl  channel activity; all of this will lead to the allevi-
ation of diarrhea. Because LPA is richly available in certain
forms of foods (14, 15), our proof of concept study might pave
the way for the use of certain diets to control diarrhea.
MATERIALS AND METHODS
Tissue culture and transfection. HT29-CL19A, Calu-3, and BHK
(baby hamster kidney cells) were cultured as described (30). For Ussing
Figure 8. A schematic view of LPA inhibition on CFTR-dependent 
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chamber experiments, HT29-CL19A and Calu-3 cells were grown on per-
meable filters (6.5-mm diameter). BHK cells were transfected transiently
with various wild-type Flag-tagged lysophosphatidic acid (LPA) receptors
or mutant Flag-tagged LPA2 receptors using a vaccinia virus expression sys-
tem (56). Animal protocols were approved by the Institutional Animal Care
and Use Committee at the University of Tennessee Health Science Center.
Antibodies, reagents, and constructs. Cystic fibrosis transmembrane
conductance regulator (CFTR) antibodies, R1104 monoclonal mouse anti-
body and NBD-R polyclonal rabbit antibody, have been described previously
(57). Anti-LPA2 antibody (rabbit-2143) against the last 11 amino acids (aa’s
341–351) of LPA2 and anti–Na /H  exchanger regulatory factor (NHERF)-2
antibody (rabbit-2346) against the full-length NHERF2 protein were gen-
erated by Genemed Synthesis, CA. Anti-Flag mAb, cholera toxin (CTX), and
pertussis toxin (PTX) were obtained from Sigma-Aldrich. Maltose binding
protein (MBP)-fusion proteins for COOH-terminal tails of LPA1 (aa’s 316–
364), LPA2 (aa’s 298–351), and LPA3 (aa’s 298–353) were generated using
pMAL vectors (New England Biolabs, Inc.). Flag-tagged full-length LPA2,
LPA2- STL, and LPA2-L351A were generated using pcDNA-3 vector (In-
vitrogen) and QuickChange mutagenesis kit (Stratagene). The peptide deliv-
ery system (Chariot) was procured from Active Motif. LPA 18:1, sphin-
gosine-1-phosphate (S1P), and phosphatidic acid (PA) were purchased from
Avanti Polar Lipids, Inc. Other lipids, LPA (20:4) and LPA (18:2), have been
described (21). Other reagents were described previously (30).
Pull-down assay. Pull-down assay was performed as described (30). In brief,
BHK or COS-7 cells expressing Flag-tagged LPA receptors (or CFTR) were
lysed in lysis buffer (PBS 0.2% Triton X-100 plus protease inhibitors). Cell ly-
sates were mixed at 4 C for 15 min followed by centrifugation at 15,000 g for
10 min at 4 C. Glutathione S-transferase (GST), GST–NHERF1, and GST–
NHERF2 (0–3  M) were added and mixed at 4 C with the clear supernatant
or MBP-C–LPA2 for the direct binding between MBP-C–LPA2 and GST–
fusion proteins. After 30–60 min incubation, glutathione sepharose beads (20
 l) were added and mixed for an additional 3 h. Thereafter, the mixture was
spun at 800 g for 2 min, and the beads were washed three times with the same
lysis buffer before the proteins were eluted from beads with Laemmli sample
buffer (containing 2.5%  -mercaptoethanol). Eluates were separated on 4–15%
gel, and were immunoblotted with anti-FLAG and anti-LPA2 antibodies.
Coimmunoprecipitation and immunoblotting. Cells were harvested
and processed as described previously (30). In brief, BHK cells (cross-linked
with dithiobis(succinimidyl)propionate as described before [reference 30]) and
epithelial cells (HT29-CL19A and Calu-3) were solubilized in RIPA buffer
(plus protease inhibitors) on ice for 20 min, and lysates were spun at 15,000 g for
15 min at 4 C to pellet insoluble material. Protein concentration of the cell ly-
sates was determined by the bicinchoninic assay (Pierce Chemical Co.). For
coimmunoprecipitation, CFTR monoclonal antibody (R1104 IgG, 1.0  g)
was cross-linked to 20  l protein A/G agarose as described previously (57). The
supernatant was incubated with the cross-linked beads overnight at 4 C under a
constant mixing. The beads were washed three times with RIPA buffer before
the immunoprecipitated proteins were eluted with sample buffer containing
2.5%  -mercaptoethanol. The immunoprecipitated proteins were separated on
4–15% gel, and blotted using polyclonal anti-NHERF2 IgG, anti-LPA2 IgG,
and anti-CFTR IgG (NBD-R IgG). For immunoblotting, cell lysates were sep-
arated on 4–15% SDS-PAGE, transferred to PVDF membranes, and immuno-
blotted for CFTR, NHERF2, and LPA2 using specific antibodies.
Short-circuit current measurements. Calu-3 and HT29-CL19A polar-
ized cell monolayers were grown to confluency on Costar Transwell permeable
supports (filter area is 0.33 cm2). Filters were mounted in an Ussing chamber,
and short-circuit currents (Isc) mediated through CFTR Cl  channel were per-
formed as described (30). Epithelia were bathed in Ringer’s solution (mM) (se-
rosal/basolateral: 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3 CaCl2,
0.5 MgCl2, 4.2 NaHCO3, 10 Hepes, 10 glucose, pH 7.2, [Cl ]   149), and
low Cl  Ringer’s solution (mM) (luminal/apical: 133.3 Na-gluconate, 5 K-glu-
conate, 2.5 NaCl, 0.36 K2HPO4, 0.44 KH2PO4, 5.7 CaCl2, 0.5 MgCl2, 4.2
NaHCO3, 10 Hepes, 10 mannitol, pH 7.2, [Cl]   14.8) at 37 C, and gassed
with 95% O2 and 5% CO2. LPA (20:4) was added into the luminal and serosal
sides of the cell monolayers for 30 min before ADO was added into the luminal
side. In parallel, some filters also were pretreated for 30 min with PA (0–35
 M) and S1P (0–35  M) before ADO addition. CFTR Cl  channel inhibitor
DPC (500  M; added into luminal side) was used to inhibit the Cl  currents
toward the end of the experiment.
To demonstrate the effect of LPA on Cl  transport in the mouse mucosa,
the mice were killed, and the distal small intestine ( 2–4 cm proximal to the
cecum) was removed and immediately placed in ice-cold, oxygenated Ringer
solution, and opened along the mesenteric border. Indomethacin (10  M) was
present in the rinse and experimental Ringer solutions to prevent prostanoid
generation during tissue manipulation. A patch of small intestine proximal to
the cecum was stripped of serosal and smooth muscle layers (34) before being
mounted in a Ussing chamber (0.112 cm2 exposed surface area). Any nerve
plexus activity in the partially remaining myenteric plexus was blocked by tetro-
dotoxin acetate (1  M), and local prostaglandin E production was inhibited by
indomethacin (10  M). LPA (20:4; 0–35  M) was added into the luminal and
serosal sides of the isolated mouse intestine for 30 min. cpt-cAMP (0–100  M)
or ADO (0–100  M) were applied to both sides to elicit a CFTR-dependent
Cl  current response, followed by luminal addition of diphenylamine-2-car-
boxylate (DPC; 500  M) toward the end of the experiment. The epithelial in-
tegrity was monitored by passing a 3-mV pulse (for cultured cells) or 0.5-mV
pulse (for isolated intestinal preparation) across the epithelia every min during
the entire experiments.
Intestinal fluid secretion (in vivo) experiments. The method of Verk-
man’s group was followed with modifications (38). CD1 mice (body weight
20–22 g; obtained from Charles River Laboratories) were held off food for 24 h
before inducing anesthesia using pentobarbital (60 mg/kg). Mouse body tem-
perature was maintained at 36–38 C during surgery using a circulating water
heating pad. A small abdominal incision was made to expose the small intestine.
Ileal loops ( 20 mm) proximal to the cecum were exteriorized and isolated
(two loops per mouse: 1 loop PBS, 1 loop PBS plus CTX). The closed-loops
were injected with 100  l PBS alone or PBS containing CTX (1–100  g). The
control and CTX-injected loops were tested in the presence and absence of
LPA (10–40  M). The abdominal incision and skin incision were closed with
wound clips, and the mice were allowed to recover. Intestinal loops were col-
lected in a terminal procedure 6 h later. PA (10–100  M) and S1P (10–100
 M) also were used in parallel experiments as described above.
In the open-loop mouse model of secretory diarrhea, mice were given sin-
gle doses of CTX (1, 10, or 100  g) dissolved in 100  l 7% NaHCO3 buffer
(or buffer alone) in the presence or absence of LPA 20:4 (BSA-complexed, 75,
250, or 750  g/kg body weight) delivered by an orogastric feeding needle. In
some experiments, oral administration of LPA 20:4 (BSA-complexed, 1,000
 g/kg body weight) was performed at different time points (0–2 h) after CTX
feeding. 6 h later, the mice were killed. The entire small intestine (from pylorus
to cecum) was exteriorized and isolated with care to avoid tissue rupture and
fluid loss. The associated mesentery and connective tissues were removed, and
the weight of the intestinal tissue and the enclosed fluid was determined. The
intestine was opened longitudinally to remove luminal fluid by blotting, and
was weighed again. Intestinal fluid accumulation was determined from the ratio
of intestinal weight before/intestinal weight after luminal fluid removal.
Macromolecular complex assembly. This assay (24) was performed us-
ing maltose binding protein (MBP)-CFTR-C tail fusion protein (1  M)
immobilized on amylose beads (20  l) and incubated with GST–NHERF2.
This step, which is called pairwise binding, was done in 200  l lysis buffer
(PBS-0.2% Triton X-100 plus protease inhibitors) and mixed at 22 C for 2 h.
The complex was washed once with the same buffer, and allowed to bind
Flag-tagged LPA2 from lysates of BHK cells expressing the receptor. The
binding was done at 4 C for 3 h with constant mixing. The complex was
washed with lysis buffer, eluted with sample buffer, and analyzed by immu-
noblotting using anti-Flag mAb.JEM VOL. 202, October 3, 2005 985
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Delivery of LPA2 receptor-specific peptide and immunostaining.
Delivery of LPA2-specific peptide was performed using the Chariot system ac-
cording to the manufacturer’s instructions (Active Motif) (45). In brief, 1.2  M
peptide containing the PDZ motif of LPA2 (last 11 aa’s, 341–351, ENGH-
PLMDSTL) was mixed with Chariot solution (total volume: 400  l) at room
temperature for 30 min. The Chariot-peptide complex was added to luminal
and serosal sides of polarized Calu-3 and HT29-CL19A cells grown on perme-
able supports and incubated for 1 h at 37 C in a humidified atmosphere con-
taining 5% CO2 before mounting in an Ussing chamber. At the end of the ex-
periment, the epithelial cells were fixed and immunostained for the efficiency of
the peptide delivery using anti-LPA2 antibody, and were subjected to immuno-
fluorescence confocal microscopy. Other peptide (CFTR peptides, aa’s 107–
117) also was delivered as described before as a control.
Cell-attached single-channel recordings. Single-channel recordings
were obtained from HT29-CL19A cells using the cell-attached configuration
(58). Patch-clamp pipettes were obtained using quartz class (Sutter Instrument
Co.), and a Sutter model P-2000 puller and had resistance of 6–8 M . The ex-
tracellular (pipette and bath) solution contained 140 mM NMDG-Cl, 2 mM
MgCl2, 2 mM CaCl2, 10 mM Hepes, and 200  M DIDS (to block non-CFTR
anion channel pharmacologically) titrated to a pH of 7.4 with NMDG. CFTR
channels were activated with 2  M ADO or 10  M forskolin included in the
pipette or bath solution as indicated. Single-channel currents were recorded
continuously for 5 min at a test potential of 60 mV (referenced to the cell inte-
rior) delivered from the recording electrode, and were filtered at 1 kHz and
sampled at 2 kHz. All experiments were conducted at room temperature (22–
24 C) using an EPC-9 patch clamp amplifier (HEKA Electronik GmbH) and
the Pulse   PulseFit V 8.65 acquisition program (HEKA Electronik GmbH).
Data analysis was performed using TacX4.1.5 (Bruxton Corp.).
Measurement of cAMP level in cultured cells and intestine tissue.
Calu-3 or HT29-CL19A cells were cultured (100- l volumes) in standard
96-well microplates (tissue-culture grade), with cell concentrations of be-
tween 104–106 cells/ml. The plates were incubated overnight at 37 C (5%
CO2 and 95% humidity). On the third day, the medium was decanted and
100  l PBS (  LPA) was added and incubated for 20–30 min before the
addition of agonists (ADO, or CFTR agonist cocktail) and incubation for
another 5 min. The cells were lysed, and intracellular cAMP levels were
measured using a cAMP Biotrak competitive enzyme immunoassay system
(GE Healthcare) according to the manufacturer’s instructions. For the mea-
surement of cAMP levels in the native intestine tissue, ileal loops ( 2 cm)
were exposed to 0.25–100  g CTX. After 6 h of CTX treatment, the ex-
cised tissue sections were frozen rapidly in liquid nitrogen and samples were
stored at  20 C until the cAMP assay was performed using the liquid phase
extraction method according to the manufacturer’s instructions (cAMP
Biotrak enzyme immunoassay, GE Healthcare).
Statistical analysis. Results are presented as mean   SEM for the indi-
cated number of experiments. Statistical analyses were performed using Stu-
dent’s t test and one-way ANOVA. A value of P   0.05, P   0.01, or P  
0.001 was considered to be statistically significant.
Online supplemental material. Fig. S1 shows that LPA2 mRNA is de-
tected in mouse intestinal tissue and various epithelial cells. Fig. S2 shows
that LPA2 interacts preferentially with NHERF2. Fig. S3 shows that LPA
inhibits CFTR-dependent Cl  currents in isolated intestine epithelia, but
failed to inhibit Cl  currents when CFTR was activated by cocktail. Fig. S4
shows the single-channel recordings of CFTR in cell-attached configura-
tion in HT29-CL19A cells in response to cpt-cAMP stimulation with or
with LPA pretreatment. Fig. S5 shows that CTX induced a dose-dependent
increase of cAMP production in gut tissue, and intact LPA is recovered 2 h
later from intestine when complexed with BSA. Fig. S6 shows that LPA2-
specific peptide prevented the LPA inhibition of CFTR-mediated Isc in po-
larized Calu-3 cells. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050421/DC1.
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